This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
These five students are a fantastic cohort of health law policy, biotechnology, and bioethics scholars who join us from Harvard Law School. At the law school, Adithi is interested in examining how emerging biotechnologies in regenerative medicine intersect with patient privacy and other ownership rights.
The HIPAA Problem The privatization of next-generation medicaltechnologies, especially in regenerative and precision medicine, further muddies the data-protection waters. The innovation-security tradeoff is a familiar trope in biotechnology, but the main character of the direct-to-consumer tissue-based service story is less so.
The emergence of digital platforms and related technologies are transforming healthcare and creating new opportunities and challenges for all stakeholders in the medical space.
Additionally, it is yet to be determined how the new AI Act will synchronize with other legislative proposals like the European Health Data Space (EHDS) , and existing EU regulations such as the General Data Protection Regulation (GDPR) and the Medical Device Regulation (MDR).
While demonstrating the artificial distinction between those concepts, the comparison highlighted Israeli regulation as presenting a clear and wide spectrum of clinical diagnostic criteria as well as a relatively generous funding scheme for medically-indicated egg freezing. The Israeli situation is a unique example of this overall trend.
Activists anticipated the rise of vaccine, therapeutic, and testing nationalism — with rich countries securing preferential access to COVID-19 medicaltechnologies and preventing export to other countries even before they had been approved — and the press soon followed.
Ivor Campbell, CEO of Snedden Campbell The global landscape for medicaltechnology, biotechnology, and life sciences is on the cusp of seismic change. About Ivor Campbell Ivor Campbell is Chief Executive of Angus-based Snedden Campbell, a specialist recruitment consultant for the medicaltechnology industry.
We organize all of the trending information in your field so you don't have to. Join 19,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content